Molecularly targeted therapy for pediatric brain tumors (Q36272981)

13 August 2017

1 reference

title

Molecularly targeted therapy for pediatric brain tumors (English)

1 reference

13 August 2017

1 reference

Warren K E

1

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Journal of Neuro-Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

75

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

335-343

1 reference

Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11060-005-6765-5

Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-005-6765-5

Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-005-6765-5

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-005-6765-5

21 January 2018

1 reference

12 December 2020

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

1 reference

12 December 2020

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

1 reference

12 December 2020

New therapeutic agents targeting the epidermal growth factor receptor.

1 reference

12 December 2020

Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma

1 reference

12 December 2020

A PDGF-regulated immediate early gene response initiates neuronal differentiation in ventricular zone progenitor cells

1 reference

12 December 2020

Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and in vivo

1 reference

12 December 2020

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood

1 reference

12 December 2020

Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells.

1 reference

12 December 2020

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

1 reference

12 December 2020

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

12 December 2020

The role of structure in kinase-targeted inhibitor design.

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour

1 reference

12 December 2020

Immature neurons from CNS stem cells proliferate in response to platelet-derived growth factor.

1 reference

12 December 2020

Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma

1 reference

12 December 2020

Regulation of transmembrane signaling by receptor phosphorylation

1 reference

12 December 2020

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

1 reference

12 December 2020

The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

Signal transduction by receptors with tyrosine kinase activity

1 reference

12 December 2020

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

1 reference

12 December 2020

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

1 reference

12 December 2020

Ras in signal transduction

1 reference

12 December 2020

Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling

1 reference

12 December 2020

Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells

1 reference

12 December 2020

Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice

1 reference

12 December 2020

GTPase activating proteins

1 reference

12 December 2020

Malignant glioma: genetics and biology of a grave matter.

1 reference

12 December 2020

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

12 December 2020

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

1 reference

12 December 2020

Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation With Gene Expression Patterns

1 reference

12 December 2020

Platelet-derived growth factor-B and -C and active alpha-receptors in medulloblastoma cells.

1 reference

12 December 2020

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

12 December 2020

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.

1 reference

12 December 2020

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

12 December 2020

Gefitinib, a novel, orally administered agent for the treatment of cancer

1 reference

12 December 2020

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations

1 reference

12 December 2020

( )-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent

1 reference

12 December 2020

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

1 reference

12 December 2020

Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.

1 reference

12 December 2020

PDGF-BB exerts trophic activity on cultured GABA interneurons from the newborn rat cerebellum

1 reference

12 December 2020

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

12 December 2020

Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas.

1 reference

12 December 2020

Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression

1 reference

12 December 2020

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide

1 reference

12 December 2020

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

1 reference

12 December 2020

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

12 December 2020

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

1 reference

12 December 2020

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

12 December 2020

The promise of targeted therapy: cancer drugs become more specific

1 reference

12 December 2020

Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

1 reference

12 December 2020

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.

1 reference

12 December 2020

The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.

1 reference

12 December 2020

Why the epidermal growth factor receptor? The rationale for cancer therapy

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Proliferation of human malignant astrocytomas is dependent on Ras activation

1 reference

12 December 2020

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

1 reference

12 December 2020

Platelet-derived growth factor in human glioma

1 reference

12 December 2020

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

1 reference

12 December 2020

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

1 reference

12 December 2020

Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis

1 reference

12 December 2020

Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.

1 reference

12 December 2020

Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma

1 reference

12 December 2020

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

12 December 2020

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

1 reference

12 December 2020

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.

1 reference

12 December 2020

10.1007/S11060-005-6765-5

Identifiers

DOI

1 reference

13 August 2017

1 reference